Author Archives: Vijaya Iyer, PhD

HRA Pharma Prepares Observational Post-Approval Study of Ketoconazole

After receiving the approval of ketoconazole for the treatment of Cushing’s syndrome patients in the European Union, HRA Pharma is setting up to conduct a post-approval observation study that will closely monitor patients receiving the therapy for any adverse events. The study is part of the mandatory pharmacovigilance…

Pituitary Tumors Affect Patients’ Ability to Work, Reduce Quality of Life

Pituitary tumor conditions, such as Cushing’s disease, have a substantial effect on patients’ work capabilities and health-related quality of life, researchers from The Netherlands reported. The study, “Work disability and its determinants in patients with pituitary tumor-related disease,” was published in the journal Pituitary. Pituitary tumors, like…

Fluconazole Found to Be Safe Alternative for Patient with Recurrent Cushing’s, Case Report Shows

Treatment with fluconazole after cabergoline eased symptoms and normalized cortisol levels in a patient with recurrent Cushing’s disease who failed to respond to ketoconazole, a case study reports. The case report, “Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease:…